Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00835328 · ClinicalTrials.gov registry record · Phase 1
Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia
A Phase 1 study, sponsored by Diva De Leon.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00835328 is a Phase 1 study that was terminated before completion, run by Diva De Leon. The registered enrollment target is 14 participants.
The verdict
NCT00835328, a Phase 1 study, was terminated before completion, sponsored by Diva De Leon.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The primary aim of this study is to evaluate the effect of Exendin (9-39) on glucose requirements to maintain euglycemia in pediatric patients with congenital hyperinsulinism (CHI) who have failed medical therapy. The secondary aims are to determine the therapeutic plasma levels, plasma half-life and pharmacokinetics of Exendin (9-39) during a 9-hour intravenous infusion.
Interventions
- DRUG Vehicle
- DRUG Exendin (9-39)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2009-08-26 |
| Est. Completion | 2017-01-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00835328
The ClinicalTrials.gov registry entry for NCT00835328 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Diva De Leon, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT00835328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00835328 about?
NCT00835328 is a clinical study titled "Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia". The primary aim of this study is to evaluate the effect of Exendin (9-39) on glucose requirements to maintain euglycemia in pediatric patients with congenital hyperinsulinism (CHI) who have failed medical therapy. The secondary aims are to determine the therapeutic plasma levels, plasma half-life an...
What is the current status of trial NCT00835328?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2009-08-26. Estimated completion is 2017-01-28.
What interventions are being tested in trial NCT00835328?
The interventions under investigation include: Vehicle (DRUG), Exendin (9-39) (DRUG).
Who is sponsoring clinical trial NCT00835328?
This trial is sponsored by Diva De Leon, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.